This article argues for the adoption of a combined lyophilized plasma and platelet product strategy to address critical gaps in forward-deployed military trauma care. The author contends that current U.S. military medical doctrine is insufficient for large-scale combat operations (LSCO) where rapid medical evacuation is not guaranteed. The paper highlights the logistical challenges and limitations of using fresh whole blood and Walking Blood Banks (WBB) in austere environments. The reader is provided with a comprehensive analysis of the operational and clinical feasibility of using freeze-dried plasma and platelets as a bridge therapy. The article reviews key clinical trials, such as the PAMPer and FLyP trials, which demonstrate the effectiveness of lyophilized products in improving patient outcomes. It further explains the hemostatic mechanisms of both lyophilized plasma and platelets and how their combined use can address trauma-induced coagulopathy more effectively. The author proposes a phased implementation plan, including immediate actions for doctrine and training development and long-term strategies for clinical research and materiel integration. The article concludes that this approach is a viable solution to enhance resuscitation capabilities and reduce preventable deaths from hemorrhage in future combat scenarios.
| Published: | April 7, 2026 |
The Center for Army Lessons Learned leads the Army Lessons Learned Program and delivers timely and relevant information to resolve gaps, enhance readiness, and inform modernization.
The Center for Army Lessons Learned leads the Army Lessons Learned Program and delivers timely and relevant information to resolve gaps, enhance readiness, and inform modernization.
